Keywords: Allergan, Botox, Migraine, Regulators, Payers, Datamonitor

Approval of Allergan’s Botox for migraine “a headache for regulators and payers,” says Datamonitor

Article | 30 July 2010

Print This

Decisions from US and European regulators on the use of Allergan’s wrinkle reducer Botox (onabotulinumtoxin A) for the prophylactic ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in